Biogen & Alkermes get NDA for MS drug
The FDA has accepted the New Drug Application (NDA) for Biogen & Alkermes’ Diroximel Fumarate in multiple sclerosis (MS).
Read More
Tag: Biogen & Alkermes
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
